Compensation for Neurodegeneration by Hippocampal Neurogenesis in Alzheimer’s Disease: Where is the Way?
Compensation for Neurodegeneration by Hippocampal Neurogenesis in Alzheimer’s Disease: Where is the Way?
复制标题
DOI：
10.1007/s12264-021-00660-5
复制
发表时间：
2021-04
影响因子：
5.6
通讯作者：
Jie Zheng;Yawen Li
中科院分区：
文献类型：
--
作者：
Jie Zheng;Yawen Li
神经变性是阿尔茨海默病(AD)的一个明显特征，其特征是神经元结构和功能的进行性丧失。治疗阿尔茨海默病的方法显示，到目前为止，在阻止神经退行性变方面效果有限。鉴于成人大脑的大多数区域缺乏神经元的更新性，对症药物或治疗方法无法在AD患者中重新填充神经元并重新连接退化的神经元回路。将新的神经元引入AD大脑，无论是通过促进固有的海马神经发生、移植外部细胞，还是体内胶质动脉瘤转化，都为AD的治疗提供了新的曙光。Schweitzer等人。已经报道了干细胞疗法在帕金森氏病神经修复中的良好结果[1]，这种疾病具有阿尔茨海默病的神经退化特征。这项临床试验再次引发了人们对阿尔茨海默病基于神经发生的治疗的可能性的担忧。然而，这些促进神经源性的策略是否提高了AD的希望或炒作仍然难以捉摸。在这里，我们讨论了在AD中研究神经发生的利弊，并呼吁通过增加新的神经元来重新考虑当前的AD治疗策略(图1)。
Neurodegeneration, a defining hallmark of Alzheimer’s disease (AD), features the progressive loss of neuronal structure and functions. Therapeutic approaches to AD show limited efficiency in halting the neurodegeneration to date. Given the lack of neuronal renewability in most subareas of the adult brain, symptomatic drugs or treatments cannot repopulate neurons and rewire the degenerated neuronal circuits in AD. Introducing new neurons into AD brains, by either promoting innate hippocampal neurogenesis, transplanting external cells, or in vivo glianeuron conversion, shines new light on AD treatment. Schweitzer et al. have reported good outcomes of stem cell-based therapies in the neural repair of Parkinson’s disease [1], which shares the neurodegenerative character of AD. This clinical trial raises again concerns about the potential of neurogenesis-based therapies for AD. However, whether these pro-neurogenic strategies raise hope or hype for AD remains elusive. Here, we discuss the pros and cons of studying neurogenesis in AD, and call for a reconsideration of current AD therapeutic strategies by adding new neurons (Fig. 1).